

LSP Life Sciences Fund

LSP
Life Sciences Partners

Monthly Report July 2014

NAV per Share

€ 144.88

Performance

YTD	1 Month	3 Months	1 Year	2 Years	Since inception
8.2%	-9.6%	-1.9%	8.6%	60.6%	44.9%

NAV of Fund

64,152,645

Number of Shares

442,793

Valuation Date

31/07/2014

Top-5 performers

1. Galapagos	5.8%
2. MorphoSys	4.7%
3. Clinigen Group	0.7%
4. Sphere Medical	0.2%
5. InterMune	-0.6%

Inception date:

27/04/2011

Currency:

Euro

Domicile:

The Netherlands

Legal Structure:

Dutch NV with variable capital

Listing:

Euronext Amsterdam

Euronext code:

LSP

ISIN Code:

NL0009756394

Bloomberg:

LSP NA


Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical-, specialist pharmaceutical-, medical device-, drug delivery-, vaccine- and diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with a market capitalization of below € 1 billion at the time of investment.

Manager's comments

The LSP Life Sciences fund had a negative return for the month of July. The biggest negative impact was from AcetRx, a company seeking FDA approval to launch a pain medication drug/device combination product for use in hospitals. Instead of the outright approval anticipated in July 27th, the FDA issued a 'Complete response letter' which asked for clarification on a number of points. This caused the share price to drop over 40% on the day of the announcement. While the points raised by the FDA appear to be relatively minor, it does mean a delay of approximately 6 months to US launch. Sphere Medical announced the long anticipated CE mark approval of their blood gas monitoring device, Proxima. This will allow the company to initiate the confirmatory studies needed for a UK launch later this year. Two new investments were added to the portfolio in July. Clinigen Group; a specialty pharma company with a unique business profile which includes a portfolio of marketed niche products and Collectis; an early stage drug development company with cutting edge technology which could lead to the development of truly ground breaking treatments for cancer.

Portfolio breakdown



Important information

LSP Advisory B.V. (as Fund Manager) and the LSP Life Sciences Fund N.V. (the Fund) have a license and are registered pursuant to the Dutch Act on Financial Supervision and are supervised by the Stichting Autoriteit Financiële Markten (Dutch Authority for the Financial Markets) and De Nederlandsche Bank N.V. (the Dutch Central Bank). This presentation is solely for information purposes and is not intended as advice in any way. The Fund Manager and the Fund cannot be held liable or responsible for the content of this presentation. Potential investors are advised to contact their investment- and fiscal advisor prior to taking an investment decision. There are risks involved in the investment. The value of the investment can fluctuate. Results achieved in the past offer no guarantee for the future. A Key Investor Information Document is also available for this product with information about the product, the costs and the risks involved. Read it before you invest in the product. The prospectus and the Key Investor Information Document of the LSP Life Sciences Fund can be downloaded via www.lspvc.com/funds/public.html

LSP Life Sciences Fund

Portfolio breakdown

Company	Stage	Subsector	Marketcap	%
InterMune	Market	Therapeutics	Mid	10.2%
Innate Pharma	Early	Therapeutics	Small	8.2%
Prosensa	Late	Therapeutics	Small	7.8%
Genmab	Market	Therapeutics	Mid	7.4%
Ablynx	Early	Therapeutics	Small	7.2%
Enanta Pharmaceuticals	Late	Therapeutics	Small	6.6%
Neurocrine Biosciences	Late	Therapeutics	Small	6.2%
Lombard Medical	Late	Medical Device	Micro	5.8%
MorphoSys	Early	Therapeutics	Mid	5.6%
GW Pharmaceuticals	Market	Therapeutics	Mid	4.9%
AceLRX	Late	Medical Device	Small	4.8%
Sphere Medical	Market	Medical Device	Micro	4.3%
NeoStem	Late	Therapeutics	Small	4.2%
Auspex Pharmaceuticals	Late	Therapeutics	Small	4.0%
Clinigen Group	Market	Specialty Pharma	Small	3.6%
Orexigen Therapeutics	Late	Therapeutics	Small	2.9%
Collectis	Early	Therapeutics	Small	2.7%
Synergy Pharmaceuticals	Late	Therapeutics	Small	0.4%